Harper Molly's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Dec 19, 2023
- Accession no.
- 0001161697-23-000629
- Filed
- Dec 19, 2023
- Trade date
- Dec 15, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $201.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harper MollyCIK 0001871470 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2023 | Common stock, par value $0.001 per share | SSaleDisposed | −4,000 | $14.43F1 | −$57,720 | 0 | Direct | |
| Dec 15, 2023 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +10,000 | $5.78 | +$57,800 | 10,000 | Direct | |
| Dec 15, 2023 | Common stock, par value $0.001 per share | SSaleDisposed | −10,000 | $14.37F1,F2 | −$143,700 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2023 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 130,764 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.
Referenced by the price of 2 transactions in Table I.
- F2
Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $14.37 to $14.40 per share.
Referenced by the price of 1 transaction in Table I.